Universidad Peruana Cayetano Heredia

Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis

Mostrar el registro sencillo del ítem

dc.contributor.author García Lescano, Héctor Hugo
dc.contributor.author Lescano Guevara, Andres Guillermo
dc.contributor.author Gonzales, Isidro
dc.contributor.author Bustos Palomino, Javier Arturo
dc.contributor.author Pretell, E. Javier
dc.contributor.author Horton, John
dc.contributor.author Saavedra Pastor, Herbert
dc.contributor.author Gonzalez Zariquiey, Armando Emiliano
dc.contributor.author Gilman, Robert Hugh
dc.date.accessioned 2019-02-06T14:45:34Z
dc.date.available 2019-02-06T14:45:34Z
dc.date.issued 2016
dc.identifier.uri https://hdl.handle.net/20.500.12866/5066
dc.description.abstract Background. The efficacy of current antiparasitic treatment for cerebral Taenia solium cysticercosis with either albendazole (ABZ) or praziquantel (PZQ) is suboptimal. A recent study demonstrated that combining these 2 antiparasitic drugs improves antiparasitic efficacy. We present here the parasiticidal efficacy data obtained during a previous phase II pharmacokinetic study that compared combined ABZ plus PZQ with ABZ alone. Methods. The study was a randomized, double-blinded, placebo-controlled phase II evaluation of the pharmacokinetics of ABZ (15 mg/k/d, for 10 days) and PZQ (50 mg/k/d, for 10 days) in intraparenchymal brain cysticercosis. Patients received the usual concomitant medications, including an antiepileptic drug (phenytoin or carbamazepine), dexamethasone, and ranitidine. Randomization was stratified by antiepileptic drug. Patients underwent safety laboratory evaluations at days 4, 7, and 11, as well as magnetic resonance (MR) imaging at 6 months to assess parasiticidal efficacy. Results. Thirty-two patients were included, 16 in each arm. All of them completed antiparasitic treatment and underwent follow-up brain MR imaging. Cysticidal efficacy was strikingly higher in the combined ABZ-plus-PZQ group than in the ABZ-alone group (proportion of cysts resolved, 78 of 82 [95%] vs 23 of 77 [30%] [relative risk {RR}, 3.18; 95% confidence interval {CI}, 2.08–4.88; P < .001]; patients with complete cyst clearance, 12 of 16 [75%] vs 4 of 16 [25%] [RR, 3.00; 95% CI, 1.23–7.34; P = .005]). Conclusions. The combination of ABZ plus PZQ is more effective in destroying viable brain cysticercosis cysts than ABZ alone. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Clinical Infectious Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject albendazole en_US
dc.subject neurocysticercosis en_US
dc.subject Peru en_US
dc.subject praziquantel en_US
dc.subject Taenia solium en_US
dc.subject Adolescent en_US
dc.subject Adult en_US
dc.subject Albendazole/pharmacology/therapeutic use en_US
dc.subject Animals en_US
dc.subject Anticestodal Agents/pharmacology/therapeutic use en_US
dc.subject Brain Diseases/drug therapy/parasitology en_US
dc.subject Female en_US
dc.subject Humans en_US
dc.subject Male en_US
dc.subject Neurocysticercosis/drug therapy/parasitology en_US
dc.subject Praziquantel/pharmacology/therapeutic use en_US
dc.subject Taenia solium/drug effects en_US
dc.subject Young Adult en_US
dc.title Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/cid/ciw134
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 1537-6591


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas